Safety and Efficacy of Adenovirus carrying Hepatocyte Growth Factor gene by Percutaneous Endocardial Injection for treating Post-infarct Heart Failure: a Phase IIa Clinical Trial.

This study was performed to evaluated the safety and efficacy of Ad-HGF by percutaneous endocardial injection for treating post-infarct heart failure.
METHODS: A total of 30 patients (15 in the experimental group and 15 in the control group) with post-infarct heart failure who were not indicated to revascularization and had received the optimal standardized medication therapy were included in the study. Percutaneous endocardial Ad-HGF gene transfer was injected with a catheter-based intramyocardial delivery system in the experimental group. Safety parameters were measured and compared between baseline and follow-ups in the experimental group. The mean difference (MD) of efficacy parameters from baseline to 6-month follow-up were measured in both groups and compared with each other.
RESULTS: No one suffered from serious adverse events in the experimental group during the 6-month follow-up. The experimental group revealed significant lower left ventricular end-diastolic dimension (LVDd) (68.5 vs. 65.8 MD: -2.69.
PMID: 29618307 [PubMed - as supplied by publisher]

Source: Current Gene Therapy - April 4, 2018 Category: Genetics & Stem Cells Authors: Meng H, Chen B, Tao Z, Xu Z, Wang L, Weizhu J, Hong Y, Liu X, Wang H, Wang L, Wu Z, Yan Z Tags: Curr Gene Ther Source Type: research